CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
1.480
+0.060 (4.23%)
Jul 25, 2025, 4:00 PM - Market closed
CASI Pharmaceuticals Revenue
CASI Pharmaceuticals had revenue of $6.24M in the quarter ending March 31, 2025, with 83.04% growth. This brings the company's revenue in the last twelve months to $31.37M, up 8.39% year-over-year. In the year 2024, CASI Pharmaceuticals had annual revenue of $28.54M, down -15.77%.
Revenue (ttm)
$31.37M
Revenue Growth
+8.39%
P/S Ratio
0.75
Revenue / Employee
$134,627
Employees
233
Market Cap
22.93M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.54M | -5.34M | -15.77% |
Dec 31, 2023 | 33.88M | -9.23M | -21.41% |
Dec 31, 2022 | 43.11M | 12.94M | 42.89% |
Dec 31, 2021 | 30.17M | 15.03M | 99.25% |
Dec 31, 2020 | 15.14M | 11.01M | 266.52% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CASI News
- 5 days ago - CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program - Accesswire
- 2 months ago - CASI Pharmaceuticals Provides Business and Clinical Update - Accesswire
- 2 months ago - CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results - Accesswire
- 2 months ago - CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China - Accesswire
- 2 months ago - CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement - Accesswire
- 4 months ago - CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company - Accesswire
- 4 months ago - CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results - Accesswire
- 7 months ago - CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Accesswire